Thermosensitive Liposomal Codelivery of HSA-Paclitaxel and HSA-Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer
- PMID: 28696100
- DOI: 10.1021/acsami.7b07132
Thermosensitive Liposomal Codelivery of HSA-Paclitaxel and HSA-Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer
Abstract
Fibrotic stroma and tumor-promoting pancreatic stellate cells (PSCs), critical characters in the pancreatic ductal adenocarcinoma (PDA) microenvironment, promote a tumor-facilitating environment that simultaneously prevents drug penetration into tumor foci and stimulates tumor growth. Nab-PTX, a human serum albumin (HSA) nanoparticle of paclitaxel (PTX), indicates enhanced matrix penetration in PDA probably due to its small size in vivo and high affinity of HSA with secreted protein acidic and rich in cysteine (SPARC), overexpressed in the PDA stroma. However, this HSA nanoparticle shows poor drug blood retention because of its weak colloidal stability in vivo, thus resulting in insufficient drug accumulation within tumor. Encapsulating HSA nanoparticles into the internal aqueous phase of ordinary liposomes improves their blood retention and the following tumor accumulation, but the large 200 nm size and shielding of HSA in the interior might make it difficult for this hybrid nanomedicine to penetrate the fibrotic PDA matrix and promote bioavailability of the payload. In our current work, we prepared ∼9 nm HSA complexes with an antitumor drug (PTX) and an anti-PSC drug (ellagic acid, EA), and these two HSA-drug complexes were further coencapsulated into thermosensitive liposomes (TSLs). This nanomedicine was named TSL/HSA-PE. The use of TSL/HSA-PE could improve drug blood retention, and upon reaching locally heated tumors, these TSLs can rapidly release their payloads (HSA-drug complexes) to facilitate their further tumor accumulation and matrix penetration. With superior tumor accumulation, impressive matrix penetration, and simultaneous action upon tumor cells and PSCs to disrupt PSCs-PDA interaction, TSL/HSA-PE treatment combined with heat exhibited strong tumor growth inhibition and apoptosis in vivo.
Keywords: HSA−drug complexes; PSCs−PDA interaction; codelivery; fibrotic matrix; pancreatic cancer; pancreatic stellate cells; thermosensitive liposomes.
Similar articles
-
Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy.J Control Release. 2020 May 10;321:564-575. doi: 10.1016/j.jconrel.2020.02.040. Epub 2020 Feb 26. J Control Release. 2020. PMID: 32112854
-
Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.Int J Pharm. 2015 Oct 15;494(1):506-15. doi: 10.1016/j.ijpharm.2015.08.055. Epub 2015 Aug 24. Int J Pharm. 2015. PMID: 26315118
-
Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.Biomaterials. 2017 Sep;140:162-169. doi: 10.1016/j.biomaterials.2017.06.021. Epub 2017 Jun 22. Biomaterials. 2017. PMID: 28651144
-
nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.Z Gastroenterol. 2014 Apr;52(4):360-6. doi: 10.1055/s-0034-1366002. Epub 2014 Mar 31. Z Gastroenterol. 2014. PMID: 24687799 Review.
-
Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer.Int J Nanomedicine. 2021 Sep 15;16:6313-6328. doi: 10.2147/IJN.S279192. eCollection 2021. Int J Nanomedicine. 2021. PMID: 34552327 Free PMC article. Review.
Cited by
-
GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs.Front Pharmacol. 2024 Jan 23;15:1329636. doi: 10.3389/fphar.2024.1329636. eCollection 2024. Front Pharmacol. 2024. PMID: 38323081 Free PMC article. Review.
-
Exploring the underlying pharmacological, immunomodulatory, and anti-inflammatory mechanisms of phytochemicals against wounds: a molecular insight.Inflammopharmacology. 2024 Oct;32(5):2695-2727. doi: 10.1007/s10787-024-01545-5. Epub 2024 Aug 13. Inflammopharmacology. 2024. PMID: 39138746 Review.
-
Development, Optimization, and Pharmacokinetics Study of Bufalin/Nintedanib Co-loaded Modified Albumin Sub-microparticles Fabricated by Coaxial Electrostatic Spray Technology.AAPS PharmSciTech. 2021 Dec 9;23(1):13. doi: 10.1208/s12249-021-02163-y. AAPS PharmSciTech. 2021. PMID: 34888752
-
Selective phytochemicals targeting pancreatic stellate cells as new anti-fibrotic agents for chronic pancreatitis and pancreatic cancer.Acta Pharm Sin B. 2020 Mar;10(3):399-413. doi: 10.1016/j.apsb.2019.11.008. Epub 2019 Nov 14. Acta Pharm Sin B. 2020. PMID: 32140388 Free PMC article. Review.
-
Nanomedicine in the Diagnosis and Treatment of Pancreatic Cancer.Pharmaceutics. 2025 Mar 31;17(4):449. doi: 10.3390/pharmaceutics17040449. Pharmaceutics. 2025. PMID: 40284444 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous